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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD), characterized as excessive lipid accumulation within
hepatocytes, is growing in prevalence. The exploitation of effective drugs for NAFLD has been proven challenging.
Herein, we aimed to establish a dietary model of hepatic steatosis using transparent zebrafish larvae in which
high-throughput chemical screens could be conducted.
Methods: Zebrafish larvae fed with high fat (HF) diet and high fat plus high cholesterol (HFC) diet were
compared to the control. We analyzed intrahepatic lipid accumulation, biological indexes and various pathways
including lipid metabolism, ER stress and inflammation. In addition, the effects of ezetimibe and simvastatin on
HFC diet-induced steatosis were evaluated.
Results: Zebrafish larvae fed with HF and HFC diets developed steatosis for 7 and 10 days. The incidence and
degree of steatosis were more severe in HFC diet-fed larvae compared with the control and HF diet-fed larvae,
suggesting that adding cholesterol to the HF diet promotes the hepatic lipid accumulation. These data were
confirmed by the pathological observation. Biological indexes, free cholesterol (FC), total cholesterol (TC) and
triacylglycerol (TG) were elevated in the liver of HFC diet-fed larvae compared with the control and HF diet-fed
larvae. Additionally, the expression levels of endoplasmic reticulum (ER) stress and lipolytic molecules (atf6,
hspa5, hsp90b1, pparab, cpt1a and acox3) were significantly up-regulated in the liver of HF and HFC diets-fed
larvae compared to the control, whereas the expression of lipogenic molecules (acaca, fasn, srebf2, hmgcs1 and
hmgcra) were decreased in the liver of HF and HFC diets-fed larvae compared to the control. To validate the
reliability of the HFC model and utility value for screening potential anti-steaotsis drugs, HFC-fed larvae were
treated with two accepted lipid-lowing drugs (ezetimibe and simvastatin). The results showed that these drugs
significantly ameliorated HFC-induced steatosis.
Conclusion: Our results demonstrate that the zebrafish larvae steatosis model established and validated in this
study could be used for in vivo steatosis studies and drug screening.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of human liver dysfunction and possesses
an enormous risk to human health [1]. It is estimated
that about 20 %-30 % of the general population suffer
from simple steatosis and the prevalence of non-
alcoholic steatohepatitis (NASH) is 3 %-10 % [2]. Block-
ing hepatic steatosis is crucial for preventing the
development of NAFLD. Although there have been im-
provements in the progression of hepatic steatosis to
more advanced liver inflammation owing to the changes
of lifestyle and the use of supplements [3, 4], the patho-
genesis of NAFLD remains unclear, and therapeutic
drugs are still restricted.
Rodents are the traditional model organisms used to
reveal mechanisms underlying NAFLD, as well as to test
the therapeutic potency of agents. There are many stud-
ies that have established NAFLD models in rodents
through hepatotoxic drugs and dietary treatments, as
well as genetic modification [5]. However, rodents are
unfit for high-throughput drug screening because these
animals produce small litters, mature slowly and incur
high financial costs in terms of considerable daily ex-
penditure and raising space owing to their relatively
large body size. Furthermore, rodents must be sacrificed
and their internal organs should be isolated in order to
examine their liver for abnormalities. This requirement
does not allow for continuous and real-time monitoring
of liver condition in large samples [6]. Current situation
highlights new approaches to complement rodent-based
researches. Nowadays, zebrafish (Danio rerio) with its
unique advantages in physiology, genetics and genomics,
have come to be recognized as an attractive model or-
ganism for studying human disorders and screening
drug candidates on a large scale [6–8]. Specific to the
study of NAFLD, the livers of larvae are matured by
4 days post fertilization (dpf) and possess the main types
of liver cells that are anatomically and functionally
analogous to those of mammals [9, 10]. Moreover, lipid
metabolism in zebrafish, which have been reported as
absorption occurs in the intestine tract with the help of
bile produced by the liver, cholesterol transport is medi-
ated by lipoproteins, and triglyceride is stored in intra-
muscular adipocyte, subcutaneous, and visceral, are
similar to humans [11, 12]. Additionally, lipid accumula-
tion can be visualized directly in the livers of transparent
larvae and chemical agents can be simply added to fish
water [13–15]. These advantages make them a powerful
system for studying lipid-related liver disease and asses-
sing the effects of drugs across hundreds of fishes via a
relatively simple protocol in vivo.
Zebrafish models of NAFLD are well established by
mutagenesis or transgenic technology, chemical and
dietary treatment in recent years [6, 8]. Studies have
shown that zebrafish develop hepatic steatosis in response
to methionine metabolism disorder [16], endoplasmic
reticulum stress [17, 18] and aberrant β-hydroxybutyrate
transport [19]. Hepatotoxic small molecules, such as
thioacetamide, tunicamycin and γ-hexachlorocyclohexane
cause an increase of hepatic lipid content [20–23].
Dietary-induced models of NAFLD in adult fish have in-
volved forced overfeeding or high-fat diet [24–26]. Based
on previous reports, there has been a lack of knowledge
about diet-induced steatosis in larval zebrafish. Recently,
Sapp et al. have reported that zebrafish larvae treated with
fructose exhibited steatosis and inflammation, indicating
that zebrafish larvae is a promising model organism to
study diet-induced steatosis [27]. Along with an increase
use of fructose, a growing consumption of high fat and
cholesterol-enriched food, have been implicated in the rise
of obesity and the prevalence of NAFLD [28, 29]. Further-
more, various evidences indicate that dietary cholesterol
plays a critical role in the development of steatosis and the
progression to steatohepatitis [29–31]. Herein, we fed lar-
vae a high fat diet alone or combined with high cholesterol
diet to induce steatosis and determined whether the hep-
atic manifestations in these fishes were similar to those of
humans. In addition, ezetimibe and simvastatin were used
to confirm the reliability of HFC diet-induced hepatic
steatosis model in larvae. Our results indicate that the
zebrafish larvae hepatic steatosis model developed in this
study is convenient and low-cost for rapid assessment of
anti-steatosis agents.
Methods
Zebrafish care and feeding
Wild-type AB stains embryos were maintained according
to standard protocol [32]. Zebrafish larvae were fed with
control diet (Zeigler Bros, Inc., USA. Protein: 50 %, Fat:
12 %, Fiber: 2.5 %), HF diet (Marine Biological Science
Co, LTD of CNSIC, Tianjin, China. Protein: 50 %, Fat:
24 %, Fiber: 2.5 %) and HFC diet (2.5 % and 5.0 % wt/wt
cholesterol added to HF diet as described [33]). This
study was approved by the Animal Care and Use
Committee of Southern Medical University, Guangzhou
and every effort was made to minimize suffering.
Treatments
To optimize a protocol for exposing larvae to HF and
HFC diets, we first assessed the consumption of control
diet by zebrafish larvae. We fed 100 larvae in a 2 L fish
tank with 30 mg-180 mg per day to meet their basic en-
ergy requirement. We found that the incidence of stea-
tosis in zebrafish larvae was gradually increased with the
growing amount of feeding. Based on these results, all
types of diets given to larvae were strictly restricted as
30 mg/tank per day. Ezetimibe (Santa Cruz Biotechnology,
Texas, USA) used in this study was added directly to the
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fish tank water at concentrations of 1 μM and simva-
statin (Cayman Chemicals, Michigan, USA) was added
at 50 μg/g food. These concentrations of drugs and
methods of administration were chosen based on pre-
vious report as described [34].
Whole-mount oil red O staining
Zebrafish larvae were fasted for 24 h after feeding.
Whole larvae were then fixed in 4 % paraformaldehyde
(PFA) overnight at 4 °C and washed twice with
phosphate-buffered saline (PBS), infiltrated with 80 %
and 100 % 1,2 propylene glycol at room temperature
20 minutes respectively and stained with 0.5 % oil red O
(Cat. No.O0625, Sigma-Aldrich, St. Louis, USA) in
100 % 1,2 propylene glycol in the dark overnight at room
temperature. Stained larvae were washed with PBS and
faded the background color by washing with 100 % and
80 % of 1,2 propylene glycol for 30 min each and stored
in 80 % 1,2 propylene glycol at 4 °C. Lipid droplets in
liver tissue were observed and imaged on a bright-field
dissecting microscope (Olympus szx10, Tokoyo, Japan).
Larvae were defined positive for steatosis if the boundary
between the liver and surrounding tissue is clear and 3
or more lipid droplets were visible within the liver by
whole-mount oil red O staining.
Oil red O staining of cryosections
Larvae were fixed in 4 % PFA overnight at 4 °C and infil-
trated with 30 % sucrose overnight at 4 °C. Larvae were
embedded in Tissue-Tek OCT Compound (Sakura Japan
Co., Ltd., Tokyo, Japan) and 10 μm sections were
mounted on slides and stored at - 80 °C. Before staining
with oil red O, slides were warmed to room temperature
and immersed in 85 % and 100 % 1,2 propylene glycol
for 5 min each, and then stained with oil red O in the
dark overnight at room temperature. Slides were quickly
destained in 100 % and 85 % propylene glycol the fol-
lowing day and then washed with PBS to clean the back-
ground. Slides were visualized on an Olympus BX51
microscope.
Biological analysis
The livers of 50-70 zebrafish larvae were homogenized
in lysis buffer, centrifuged and got supernatant liquid.
FC, TC and TG in the liver homogenates were measured
using the kits (APPLYGEN Bioengineering, Beijing,
China and Nanjing Jiancheng Bioengineering, Nanjing
city, China) following the manufacturer’s instructions, and
were normalized to the total protein concentration as
determined by Bradford Assay (Bio-Rad, Hercules, CA).
Histologic analysis
Larvae were fixed with 4 % PFA overnight, embedded in
paraffin according to standard procedures. Four μm
sections were stained with hematoxylin and eosin (H&E)
and observed on BX51 microscope (Olympus, Tokyo,
Japan).
Quantitative RT-PCR
Total RNA was extracted from pools of 20-30 dissected
livers and purified using RNeasy plus mini kit (Qiagen,
German) and reverse-transcribed with qScript cDNA
using PrimeScript™ RT-PCR Kit (Takara Biotechnology
Co., Ltd., Dalian, China). Quantitative reverse-transcription
PCR (qRT-PCR) was carried out on Light Cycler 480
(Roche, Basel, Switzerland) using gene-specific primers
(Additional file 1: Table S1). eef1a1 was used as a reference,
and expression was calculated using the cycle threshold
(Ct) method (2-Ct (target)/ 2-Ct (eef1a1)).
Western blotting
Livers were dissected from pools of 20-30 larvae and
lysed in RIPA buffer supplemented with protease inhibi-
tors (Roche). The entire extract was resolved by SDS-
PAGE, transferred to a PVDF membrane (Bio-Rad)
and incubated overnight with antibodies as indicated.
Mouse monoclonal anti-GRP78/BiP (Cat.No.MB0050,
1:1000, Bioworld Technology, St.Louis Park, USA),
rabbit monoclonal anti-β-actin (Cat.No.ab151526, 1:1000,
Abcam, San Franciso, USA), goat anti-rabbit-HRP
(Cat.No.ab6721, 1:10000, Abcam), anti-mouse-HRP
(Cat.No.ab6729, 1:10000, Abcam) were used. Quantifi-
cation of band intensities was performed using Image
J software.
Statistical analyses
Statistical analysis was carried out by using SPSS 16.0 stat-
istical software. The results are expressed as mean ± SD.
Student’s t test and one-way ANOVA test are perform for
analysis. Graphpad Prism 5 software (Graphpad, La Jolla,
CA, USA) was used to draw figures. Differences were
considered significantly at P < 0.05 level.
Results
Changes in body weight and body length in the HF and
HFC diets-fed zebrafish larvae
To establish a hepatic steatosis model, 5 dpf zebrafish
larvae were treated with control, HF diet and two types
of HFC diets (2.5 % HFC diet and 5.0 % HFC diet) for 7
or 10 days (Fig. 1a). During the period of feeding, HF
diet and HFC diet did not induce significant mortality
(Fig. 1b). Body length was significantly higher in the
HF group and HFC groups compared to the control
after 7 days feeding (P < 0.01, n = 90 all), this trend
was maintained throughout the 10 days dietary proto-
col (Fig. 1c and d). Next, we pooled 10 larval zebra-
fish for each sample to measure their body weight
because the weight of a single fish was too light. The
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control group weighed significantly less than the HF
and HFC groups within 7 or 10 days feeding (P < 0.01,
n = 90 all) (Fig. 1e).
HF and HFC diets-induced hepatic steatosis in zebrafish
larvae
HF or HFC diets exposure results in steatosis and hepa-
titis in adult fish and rodents models [25, 35]. To deter-
mine whether this also occurs in larvae, zebrafish fed
with HF diet and HFC diet were stained with oil red O.
Larvae fed with control diet rarely developed steatosis
after 7 and 10 days feeding (0 % and 11 %, respectively),
whereas HF diet treatment resulted in 85 % and 98 % of
steatosis. The incidence of steatosis was much higher in
2.5 % HFC group (98 % and 100 %) and 5.0 % HFC
group (96 % and 100 %) compared with the control
(Fig. 2a and b). Lipid droplets in the hepatocytes were
further confirmed by frozen liver sections and histo-
logical analysis of larvae treated with HF and HFC diets,
but not in the control (Fig. 2c and Additional file 1:
Figure S1). Interestingly, we observed that larvae fed
with HF diet developed mild steatosis, whereas zebrafish
given HFC diet developed obvious steatosis, indicating
that dietary cholesterol may be a contributing factor in
the development of steatosis (Additional file 1: Figure S2).
Next, we measured FC, TC and TG levels in the liver ho-
mogenates isolated from the larvae. The levels of FC, TC
and TG were significantly elevated in the liver of HF
group, 2.5 % HFC group and 5.0 % HFC group compared
with the control group. However, there was no significant
Fig. 1 Effects of HF and HFC diets treatment on the survival rate and growth of zebrafish larvae. a Outline of the HF and HFC diets feeding
protocol. b Larvae treated with control, HF diet, 2.5 % diet and 5.0 % HFC diet were scored for mortality, n = 600 from 6 tanks, error bars show
standard deviation. c Standard length was measured from top to the end of the body. S.L.: standard length. d Body length and (e) body weight
were expressed as the mean ± SD, n = 90 from 3 tanks. N.S.: no significant difference, **P < 0.01, ***P < 0.001, by one-way ANOVA and LSD
post-hoc test
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difference in the expression levels of TG between HF
group and HFC group (Fig. 2d, e and f). Taken together,
these results demonstrate that HF and HFC diets lead to
steatosis and changes of biochemical indices in zebrafish
larvae within a relatively short period of time.
Genes changes in the livers of HF and HFC diets-fed
zebrafish larvae
To investigate the gene changes during HF and HFC di-
ets loading period, we analyzed the mRNA expression
levels of genes related to lipid metabolism, ER stress and
inflammation in the liver of zebrafish larvae. The expres-
sion levels of lipogenesis genes, acaca, fasn were de-
creased in the livers of HF and HFC diets-fed larvae
compared with the larvae in control group. The expres-
sion levels of cholesterol synthesis genes, srebf2, hmgcs1
and hmgcra were consistently down-regulated in the
livers of HFC diets-fed larvae compared to the control
and HF diet-fed larvae. Moreover, HF and HFC diets-fed
larvae have a significant increase in expression of cpt1a
and acox3, as well as a rise in expression of pparab
(Fig. 3a). In addition, the expression levels of ER stress
genes, atf6, hspa5 and hsp90b1 were elevated in the
livers of HF and HFC diets-fed larvae compared to the
control (Fig. 3b). Although the expression level of il6
was elevated in the livers of 5.0 % HFC diet-fed larvae
compared to the control, there were no significant differ-
ences in tnfa, il1b mRNA expression between four
Fig. 2 HF and HFC diets lead to hepatic steatosis in zebrafish larvae. a Representative image of larvae defined positive for steatosis by whole-mount oil
red O staining. Dotted line outlines the liver. b The percent of larvae with steatosis was scored in 3 tanks with at least n = 100 per group. c Numberous
lipid droplets in the hepatocytes were observed by oil red O staining of frozen liver sections and H&E staining in HF group, 2.5 % HFC group and
5.0 % HFC group after 10 days of feeding. d FC, (e) TC and (f) TG levels in livers of larvae fed with control, HF, 2.5 % HFC and 5.0 % HFC diets for 10 days
were normalized to total protein. Data are expressed as mean ± SD, N.S.: no significant difference, *P < 0.05, ***P < 0.001, by one-way ANOVA. (A, ×63
magnification; C, ×400 magnification; in: intestine)
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groups (Fig. 3c). To further study whether markers of in-
flammation would changes after longer duration of
feeding, we analyzed the mRNA expression levels of
genes related to ER stress and inflammation in the
liver of the fish after 20 days of feeding. The expres-
sion levels of atf6, hspa5, hsp90b1 and ddit3 were con-
sistently up-regulated in the liver of HF and HFC
diets-fed larvae compared to the control. Moreover,
the expression levels of inflammation genes tnfa, ilb,
and il6 were significantly elevated in the liver of HF
diet and HFC diet-fed larvae compared with the control
after 20 days of feeding (Additional file 1: Figure S3B
and S3C). These results, along with the morphologic
findings, demonstrate that HF and HFC diets treat-
ment in larvae lead to steatosis and induce the dis-
order of lipid metabolism and dysfunction of ER
within a relatively short period of time.
Ezetimibe and simvastatin treatment ameliorate hepatic
steatosis in 2.5 % HFC-fed zebrafish larvae
To validate the reliability of the HFC model and util-
ity value for screening potential anti-steaotsis drugs,
HFC-fed larvae were treated with ezetimibe and sim-
vastatin. We found that lipid droplets were decreased
in the livers of 2.5 % HFC + ezetimibe and 2.5 %
HFC + simavastatin groups compared with 2.5 % HFC
group (Fig. 4a). Consistent with the above results, the
levels of FC, TC and TG were increased in the livers
of 2.5 % HFC group compared with the control group
and were markedly decrease in the livers of 2.5 %
HFC + ezetimibe and 2.5 % HFC + simavastatin groups
(Fig. 4b, c and d). These data indicate ezetimibe and
simvastatin exhibit anti-steatosis activities, which
imply the potential of HFC model to test novel lipid-
regulating drug candidates.
Fig. 3 Genes changes in the livers of HF and HFC diets-fed zebrafish larvae. The expression levels of genes involved in (a) lipid metabolism, (b) ER
stress and (c) inflammatory pathway in HF group, 2.5 % HFC group and 5.0 % HFC group were compared with the gene expression in control
group. Gene expression analysis using cDNA prepared from pools of livers dissected from larvae (n =20-30) in each group after 10 days of feeding. Data
are expressed as mean ± SD, N.S.: no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001, by one-way ANOVA
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Effect of ezetimibe and simvastatin on genes and protein
expression profiles
2.5 % HFC diet treatment significantly decreased expres-
sion of srebf2, hmgcs1 and hmgcra. However, ezetimibe
treatment of 2.5 % HFC-fed larvae increased mRNA ex-
pression of srebf2, hmgcs1 and hmgcra, but this was not
found in 2.5 % HFC + simvastatin group (Fig. 5a). Al-
though the mRNA expression of acox3 were decreased
in the livers of 2.5 % HFC + simvastatin group compared
to 2.5 % HFC group, there were no remarkable differ-
ences in expression of pparab, cpt1a in the livers of
2.5 % HFC + ezetimibe group and 2.5 % HFC + simva-
statin group compared with 2.5 % HFC group (Fig. 5b).
Additionally, ezetimibe and simvastatin treatment could
inhibit 2.5 % HFC diet-induced ER stress and reduce the
expression of atf6, hspa5 and hsp90b1 at mRNA level.
Consistent with the changes of mRNA level, the protein
expression of GRP78/BiP was decreased in the 2.5 %
HFC + ezetimibe and 2.5 % HFC + simvastatin group
(Fig. 5c). These results suggest that ezetimibe and simva-
statin significantly ameliorate HFC-induced steatosis
might via regulating lipid metabolism or ER stress
pathway.
Discussion
Here we have demonstrated that HF and HFC diets
treatment of zebrafish larvae induced a significant
phenotype similar to human steatosis, characterized by
Fig. 4 Ezetimibe and simvastatin treatment ameliorate hepatic steatosis in 2.5 % HFC-treated zebrafish larvae. a Whole-mount oil red O staining,
oil red O staining of frozen liver sections and H&E staining of paraffin liver sections in larvae exposure to control, 2.5 % HFC, 2.5 % HFC + ezetimibe
and 2.5 % HFC + simvastatin diets. Clear cytoplasmic lipid droplets were seen in livers of larvae fed with 2.5 % HFC diet. Ezetimibe and simvastatin
treatment decreased lipid droplets in 2.5 % HFC-treated zebrafish larvae. b FC, (c) TC and (d) TG levels in livers of larvae fed with control, 2.5 % HFC,
2.5 % HFC + ezetimibe and 2.5 % HFC + simvastatin diets for 10 days were normalized to total protein. Data are expressed as mean ± SD, *P < 0.05,
**P < 0.01, ***P < 0.001, by one-way ANOVA
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excessive lipid droplets deposit in the liver and genes ex-
pression changes involved in lipid metabolism and ER
stress. Moreover, the incidence and degree of steatosis
were more severe in HFC diet-fed larvae compared with
the HF diet-fed larvae, suggesting that cholesterol
promotes the hepatic lipid accumulation. We then con-
firmed that steatosis could be ameliorated by ezetimibe
and simvastatin treatment, supporting the use of HFC
model for testing anti-steatosis drugs. This model will be
a low-cost and effective system for studying mechanisms
Fig. 5 Effect of ezetimibe and simvastatin on genes and protein expression. The expression levels of (a) srebf2, hmgcs1 and hmgcra (b) pparab,
cpt1a and acox3 (c) atf6, hspa5 and hsp90b1 in 2.5 % HFC group, 2.5 % HFC + ezetimibe group and 2.5 % HFC + simvastatin group were
compared with the gene expression in control group. Gene expression analysis using cDNA prepared from pools of livers dissected from
larvae (n = 20-30) in each group after 10 days of feeding. Fold change in GRP78/BiP protein levels normalizing to β-actin was examined
by western blot in the livers of zebrafish larvae. Data are expressed as mean ± SD, N.S.: no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001, by
one-way ANOVA
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of the pathological processes in early steatosis, as well as
for testing novel lipid-regulating agents.
The advantages of zebrafish as a model organism are
versatile. Symptomatic fish are generated quickly in large
numbers in a single experiment, which provides distinct
benefits over rodent models [6, 8]. Previous studies have
proved their utility in modeling NAFLD induced by all
kinds of mechanisms, but there has been a lack of a
tractable model to study diet-induced steatosis in larval
zebrafish [16–26]. Coincidentally, Sapp et al. have re-
cently established a fructose-induced NASH model in 7
dpf larvae, our HFC model of steatosis therefore would
be an indispensable complement for fructose model to
understand diet-induced steatosis in larval zebrafish
[27]. In contrast, our HFC model of steatosis induction
was superior and the background steatosis was inferior
to fructose model. This might because the food intake
was strictly restricted every day and the raising period
was relatively longer. Moreover, we observed that adding
cholesterol to HF diet promotes the hepatic lipid accu-
mulation by whole-mount oil red O staining. Consistent
with the staining results, hepatic FC and TC levels in
HFC group were much higher than the control and HF
groups. These findings, along with previous studies,
demonstrates that dietary cholesterol is a critical factor
in the development of steatosis and FC accumulated in
the liver is related to the severity of steatosis or liver in-
jury in larvae as well as in mammals [29–31].
Regarding to the gene changes of zebrafish during HF
and HFC diets feeding periods, we found that HF and
HFC diet-fed zebrafish possessed higher mRNA levels of
genes involved in lipid oxidation (pparab, cpt1a and
acox3) and lower mRNA levels of genes involved in lipid
synthesis (acaca, fasn, srebf2, hmgcs1 and hmgcra) than
the control diet-fed ones, suggesting that excessive fat
and cholesterol in diet stimulated the hepatic catabolic
pathway and inhibited the anabolic pathway. Further-
more, ER stress pathway which is known to incur steato-
sis, promote the progression of NASH, and activate the
inflammatory signaling was also affected [36, 37]. Here,
we found that the expression levels of atf6, hspa5 and
hsp90b1 were elevated in the livers of HF and HFC
diets-fed larvae compared to the control, indicating that
HF and HFC diets lead to the dysfunction of ER. Al-
though 10 days of HF and HFC diets exposure did not
lead to a significant elevate in liver inflammation, the ex-
pression levels of tnfa, il1b and il6 were remarkable in-
creased in the livers of HF and HFC diets-fed larvae
after 20 days of feeding. These data suggested that HF
and HFC diets lead to the disorder of lipid metabolism
and dysfunction of ER within a relatively short period of
time. Moreover, HF and HFC diets-fed larvae have a
trend toward the progression of NASH after longer dur-
ation of feeding.
The ability to conduct high-throughput drug screening
is an outstanding advantage of larvae model for NAFLD
studies. Unlike adult fish, lipids can be visualized directly
in transparent larvae and juveniles using whole-mount oil
red O staining method [13, 38–41]. This simple method
provides a high-throughput means to detect the incidence
of steatosis in larvae, enabling us to examine steatosis
across a large number of fish. Here, we chose two drugs,
ezetimibe and simvastatin, to demonstrate the validity of
our model to screen for anti-steatosis drugs. Accumulat-
ing evidences indicate that ezetimibe and simvastatin can
improve steatosis and NASH in fish models and mammals
[42–44]. In our HFC model, we also found that these two
drugs induced a significant decrease lipid accumulation in
the liver, which implies the potential of this model to test
novel lipid-regulating drugs.
Here, we established a larval zebrafish model of steatosis
within a relatively short period maintained on diets. Our
HFC diet-fed steatosis model has several advantages. First,
diet induced-steatosis most closely resembles the human
pathology of NAFLD. HFC diet is not a special diet and
easily imitates human dietary habits. Second, zebrafish
models of NAFLD in previous studies mostly focused on
the stage of early larvae and adult zebrafish, there is lack
of late larvae and early juveniles models of NAFLD. In
consideration of this, HFC model was useful for providing
more information about diet-induced steatosis in the
period of late larvae and early juveniles. Third, this model
has great potential for exploring the pathogenesis of early
steatosis and conducting high-throughput drug screening.
Nevertheless, this model has some disadvantages. For ex-
ample, female fish that rarely mated with males are apt to
have offspring with poor quality, which may cause high
mortality. Furthermore, multiple serum biochemical pa-
rameters are hard to detect because larval zebrafish are
too small to draw blood. Additionally, it’s a time-
consuming work to dissect the livers from the small fish.
In conclusion, we established a novel larval zebrafish
model of hepatic steatosis using HFC diet treatment.
This model has great potential for exploring the rela-
tionships between diet and host factors that contribute
to the pathogenesis of hepatic steatosis and the ability to
conduct high-throughput drug screening is crucial for
the development of new interventions or therapies. Our
model will provide a powerful new tool in the search for
new drugs to prevent and treat NAFLD.
Conclusion
This study developed and validated a larval zebrafish
hepatic steatosis model that could be used for in vivo
screening and efficacy assessment of anti-steatosis drugs.
This larval zebrafish hepatic steatosis model is easily
available, low-cost with a short testing time and could
speed up anti-steatosis drug research and development.
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Additional file
Additional file 1: Figure S1. HF and HFC diets lead to hepatic steatosis
in zebrafish larvae. Figure S2. Lipid accumulation in the livers and blood
vessels of zebrafish larvae fed with HF and HFC diets. Figure S3. Genes
changes in the livers of HF and HFC diets-fed zebrafish larvae. Table S1.
Primer sequences used for quantitative RT-PCR. (DOCX 2678 kb)
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palmitoyltransferase 1a; acox3: Acyl-CoA oxidase 3; atf6: Activating transcription
factor 6; eif2ak3: Eukaryotic translation initiation factor 2-alpha kinase 3;
ern2: Endoplasmic reticulum to nucleus signaling 2; hspa5: Heat shock protein 5;
hsp90b1: Heat shock protein 90, beta (grp94), member 1; ddit3: DNA-damage-
inducible transcript 3; il1b: Interleukin 1, beta; tnfa: Tumor necrosis factor a
(TNF superfamily, member 2); eef1a1: Eukaryotic translation elongation
factor 1 alpha 1.
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